However, their application for the treatment of osteogenic bone metastatic prostate cancer has not been explored thus far due to the pleiotropic and often opposing effects TGFβ can have on cancer and bone cell behavior5, 23, 24, 25. This evidence concerns the gene TGFB1 and cancer.